

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | JUN 06 | EPFULL enhanced with 260,000 English abstracts |
| NEWS | 3 | JUN 06 | KOREAPAT updated with 41,000 documents |
| NEWS | 4 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications |
| NEWS | 5 | JUN 19 | CAS REGISTRY includes selected substances from web-based collections |
| NEWS | 6 | JUN 25 | CA/CAPLUS and USPAT databases updated with IPC reclassification data |
| NEWS | 7 | JUN 30 | AEROSPACE enhanced with more than 1 million U.S. patent records |
| NEWS | 8 | JUN 30 | EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations |
| NEWS | 9 | JUN 30 | STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in |
| NEWS | 10 | JUN 30 | STN AnaVist enhanced with database content from EPFULL |
| NEWS | 11 | JUL 28 | CA/CAPLUS patent coverage enhanced |
| NEWS | 12 | JUL 28 | EPFULL enhanced with additional legal status information from the epline Register |
| NEWS | 13 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements |
| NEWS | 14 | JUL 28 | STN Viewer performance improved |
| NEWS | 15 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced |
| NEWS | 16 | AUG 13 | CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998 |
| NEWS | 17 | AUG 15 | CAOLD to be discontinued on December 31, 2008 |
| NEWS | 18 | AUG 15 | CAPLUS currency for Korean patents enhanced |
| NEWS | 19 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information |
| NEWS | 20 | SEP 18 | Support for STN Express, Versions 6.01 and earlier, to be discontinued |
| NEWS | 21 | SEP 25 | CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances |
| NEWS | 22 | SEP 26 | WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced |
| NEWS | 23 | SEP 29 | IFICLS enhanced with new super search field |
| NEWS | 24 | SEP 29 | EMBASE and EMBAL enhanced with new search and display fields |
| NEWS | 25 | SEP 30 | CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents |
| NEWS | 26 | OCT 07 | EPFULL enhanced with full implementation of EPC2000 |
| NEWS | 27 | OCT 07 | Multiple databases enhanced for more flexible patent number searching |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:13:42 ON 15 OCT 2008

| | | |
|----------------------|------------|---------|
| => file reg | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 16:13:49 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0
DICTIONARY FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s12.str



```

chain nodes :
7  8  9 10 11 12 13 14 15 17
ring nodes :
1  2  3  4  5  6 16 18 19 20 21 22
chain bonds :
1-7  4-13  7-8  7-9  7-10 10-11 11-12 13-14 14-15 15-16 15-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6 16-18 16-22 18-19 19-20 20-21 21-22
exact/norm bonds :
1-2  1-6  1-7  2-3  3-4  4-5  5-6  7-8  7-9  7-10 13-14 14-15 15-17
exact bonds :
4-13 10-11 11-12 15-16
normalized bonds :
16-18 16-22 18-19 19-20 20-21 21-22

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom

```

L1 STRUCTURE UPLOADED

```

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:14:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -            30 TO ITERATE

```

```

100.0% PROCESSED            30 ITERATIONS            12 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE    **COMPLETE**
                         BATCH    **COMPLETE**
PROJECTED ITERATIONS:            272 TO        928
PROJECTED ANSWERS:                33 TO        447

```

L2 12 SEA SSS SAM L1

```

=> s l1 sss full

```

FULL SEARCH INITIATED 16:14:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 532 TO ITERATE

100.0% PROCESSED 532 ITERATIONS 178 ANSWERS
SEARCH TIME: 00.00.01

L3 178 SEA SSS FUL L1

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 178.36 | 178.57 |

FILE 'CAPLUS' ENTERED AT 16:14:15 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 11 L3

=> d ibib abs hitstr 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:509742 CAPLUS

DOCUMENT NUMBER: 146:500900

TITLE: Preparation of piperidine glycine transporter inhibitors

INVENTOR(S): Hallett, David; Lindsley, Craig W.; Naylor, Elizabeth M.; Zhao, Zhijian; Theberge, Cory R.; Wolkenberg, Scott E.; Nolt, Brad M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited

SOURCE: PCT Int. Appl., 85pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|---|----|----------|-----------------|------------|
| WO 2007053400 | A2 | 20070510 | WO 2006-US41699 | 20061027 |
| WO 2007053400 | A3 | 20070920 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2006309050 | A1 | 20070510 | AU 2006-309050 | 20061027 |
| CA 2627177 | A1 | 20070510 | CA 2006-2627177 | 20061027 |
| EP 1942893 | A2 | 20080716 | EP 2006-826685 | 20061027 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| PRIORITY APPLN. INFO.: | | | US 2005-731010P | P 20051028 |
| | | | WO 2006-US41699 | W 20061027 |
| OTHER SOURCE(S): MARPAT 146:500900 | | | | |
| GI | | | | |



I




II

AB The title compds. I [R1 = (CH2)_nR1a (wherein n = 0-6; R1a = (un)substituted alkyl, cycloalkyl, piperidinyl, etc.); R2 = (un)substituted Ph, heterocyclyl, cycloalkyl, etc.; R3 = (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, etc.; R4, R5 = H, alkyl; or R4 and R5 taken together form a cycloalkyl ring; A = O, NR10 (R10 = H, alkyl, cycloalkyl, etc.); m = 0 or 1] that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved, were prepared E.g., a multi-step synthesis of II, starting from tert-Bu 4-cyanopiperidine-1-carboxylate and cyclopropylmethyl bromide, was given. The exemplified compds. I had activity in inhibiting specific uptake of [14C]glycine, generally with an IC50 value of less than about 10 μM. Pharmaceutical composition comprising the compound I is disclosed.

IT 936481-32-2P 936481-37-7P 936481-39-9P
936481-41-3P 936481-42-4P 936481-43-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine glycine transporter inhibitors)


RN 936481-32-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1'-(propylsulfonyl)[1,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)




RN 936481-37-7 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 936481-39-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(4-methyl-1-piperazinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 936481-41-3 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)




RN 936481-42-4 CAPLUS

CN Benzamide, N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 936481-43-5 CAPLUS

CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:410347 CAPLUS

DOCUMENT NUMBER: 146:421847

TITLE: Preparation of radiolabeled benzoic acid
piperidinylalkylamide GlyT1 glycine transporter
inhibitors for diagnostic imaging

INVENTOR(S): Burns, H. Donald; Hamill, Terence G.; Lindsley, Craig W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 30pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-------------------|------------|
| WO 2007041025 | A2 | 20070412 | WO 2006-US36989 | 20060925 |
| WO 2007041025 | A3 | 20070830 | | |
| <p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA</p> | | | | |
| EP 1942733 | A2 | 20080716 | EP 2006-815187 | 20060925 |
| <p>R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR</p> | | | | |
| PRIORITY APPLN. INFO.: | | | US 2005-721782P | P 20050929 |
| | | | WO 2006-US36989 | W 20060925 |
| OTHER SOURCE(S): | | | MARPAT 146:421847 | |
| GI | | | | |



AB Title compds. (I; A = N, CH; R2a, R2b = H, F, Cl, Br; R3 = alkyl, fluoroalkyl; R4 = H, alkyl; 1 of X, Y = ¹⁸F, O11CH3, OCD2¹⁸F, the other = H), were prepared Thus, title compound (II) was prepared by treatment of the corresponding phenol derivative with a product prepared from [¹⁸F]F⁻ and CD2Br2 in the presence of Cs2CO3 in DMF at 100°.


IT 934200-18-7P 934200-19-8P 934200-20-1P
934200-21-2P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1 glycine transporter inhibitors for diagnostic imaging)

RN 934200-18-7 CAPLUS

CN Benzamide, 2-fluoro-6-(fluoro-¹⁸F-methoxy-d2)-N-[(1S)-1-[4-phenyl-1-

(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 934200-19-8 CAPLUS


CN Benzamide, 2-chloro-6-(fluoro-18F)-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 934200-20-1 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-[3-(methoxy-11C)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 934200-21-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-[6-(fluoro-18F)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




IT 934200-22-3 934200-23-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1
 glycine transporter inhibitors for diagnostic imaging)
 RN 934200-22-3 CAPLUS
 CN Benzamide, 2-fluoro-6-hydroxy-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-
 piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 934200-23-4 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-
 piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 866559-78-6P 866559-80-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1
 glycine transporter inhibitors for diagnostic imaging)
 RN 866559-78-6 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-(6-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-

piperidinyl)methyl]- (CA INDEX NAME)



RN 866559-80-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(3-hydroxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:344575 CAPLUS

DOCUMENT NUMBER: 146:492593

TITLE: Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl)methyl benzamides

AUTHOR(S): Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; O'Brien, Julie; Lemaire, Wei; Williams, David L., Jr.; Chen, Tsing-Bau; Chang, Raymond S. L.; Burno, Maryann; Jacobson, Marlene A.; Sur, Cyrille; Kinney, Gene G.; Pettibone, Douglas J.; Tiller, Philip R.; Smith, Sheri; Tsou, Nancy N.; Duggan, Mark E.; Conn, P. Jeffrey; Hartman, George D.

CORPORATE SOURCE: Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, West Point, PA, 19486, USA

SOURCE: ChemMedChem (2006), 1(8), 807-811
CODEN: CHEMGX; ISSN: 1860-7179


PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:492593

GI



I

AB An iterative analog library synthesis approach was employed to develop SAR for the title compds. Analog I was thus identified as a novel, centrally active GlyT1 inhibitor. I enhanced prepulse inhibition in a rodent behavioral model sensitive to antipsychotic treatment.


IT 852029-09-5P 852029-12-0P 852029-23-3P
852029-28-8P 852029-36-8P 852029-37-9P
852029-44-8P 852029-47-1P 852029-48-2P
852029-50-6P 936101-97-2P 936101-98-3P
936101-99-4P 936102-00-0P 936102-01-1P
936102-02-2P 936102-03-3P 936102-04-4P
936102-05-5P 936102-06-6P 936102-07-7P
936102-08-8P 936102-09-9P 936102-10-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(piperidinylmethylbenzamide-derived glycine transporter-1 inhibitors)


RN 852029-09-5 CAPLUS

CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-(CA INDEX NAME)




RN 852029-12-0 CAPLUS

CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-(CA INDEX NAME)




RN 852029-23-3 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 852029-28-8 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-36-8 CAPLUS

CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS


CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-44-8 CAPLUS

CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-47-1 CAPLUS

CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-48-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-50-6 CAPLUS


CN Benzamide, 2-amino-6-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936101-97-2 CAPLUS

CN Benzamide, 2,4-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936101-98-3 CAPLUS


CN Benzamide, 2,4-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936101-99-4 CAPLUS

CN Benzamide, 2-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-00-0 CAPLUS

CN Benzamide, 2-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-01-1 CAPLUS

CN Benzamide, 2,4-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-02-2 CAPLUS


CN Benzamide, 2-amino-6-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936102-03-3 CAPLUS
 CN Benzamide, N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 936102-04-4 CAPLUS
 CN Benzamide, N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-
 (trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-05-5 CAPLUS
 CN Benzamide, 2-chloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-
 piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-06-6 CAPLUS

CN Benzamide, 2-fluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-07-7 CAPLUS

CN Benzamide, 2,4-difluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936102-08-8 CAPLUS


CN Benzamide, 2,4-dichloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936102-09-9 CAPLUS
 CN Benzamide, 2-amino-6-fluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936102-10-2 CAPLUS
 CN Benzamide, 2-amino-6-chloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 266341-42-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (piperidinylmethylbenzamide-derived glycine transporter-1 inhibitors)
 RN 266341-42-8 CAPLUS
 CN Benzamide, 2-methoxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
 (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1190066 CAPLUS
 DOCUMENT NUMBER: 146:142582
 TITLE: Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-

AUTHOR(S): (propylsulfonyl)piperidin-4-yl)methyl)benzamides
 Zhao, Zhijian; O'Brien, Julie A.; Lemaire, Wei;
 Williams, David L.; Jacobson, Marlene A.; Sur,
 Cyrille; Pettibone, Doug J.; Tiller, Philip R.; Smith,
 Sheri; Hartman, George D.; Wolkenberg, Scott E.;
 Lindsley, Craig W.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck and Co.,
 Inc., West Point, PA, 19486, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
 16(23), 5968-5972
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:142582
 GI



AB The synthesis and SAR of potent and selective non-sarcosine-derived GlyT1
 inhibitors is described. A library of
 N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-
 yl)methyl)benzamides was constructed using amidation as the key step.
 Some compds., e.g., I, displayed promising GlyT1 inhibitory activity.
 IT 919284-93-8P 919284-94-9P
 RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or
 recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation)
 (preparation, GlyT1 inhibitory activity and SAR of
 [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides
 starting from N-Boc cyanopiperidine using amidation as key steps)
 RN 919284-93-8 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[(1R)-1-[4-(4-morpholinylcarbonyl)-1-
 (propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 919284-94-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 869463-15-0P 869463-16-1P 919284-71-2P
 919284-72-3P 919284-73-4P 919284-74-5P
 919284-75-6P 919284-76-7P 919284-77-8P
 919284-80-3P 919284-81-4P 919284-82-5P
 919284-83-6P 919284-84-7P 919284-85-8P
 919284-86-9P 919284-87-0P 919284-88-1P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, GlyT1 inhibitory activity and SAR of
 [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides
 starting from N-Boc cyanopiperidine using amidation as key steps)

RN 869463-15-0 CAPLUS


CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 869463-16-1 CAPLUS
 CN Benzamide, 2-chloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-71-2 CAPLUS
 CN 4-Piperidinecarboxamide, 4-[[2-(2,4-dichlorobenzoyl)amino]methyl]-N,N-dimethyl-1-(propylsulfonyl)- (CA INDEX NAME)




RN 919284-72-3 CAPLUS
 CN 4-Piperidinecarboxamide, 4-[[2-(2,4-dichlorobenzoyl)amino]methyl]-N-ethyl-1-

(propylsulfonyl)- (CA INDEX NAME)




RN 919284-73-4 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-74-5 CAPLUS


CN 4-Piperidinecarboxamide, N-cyclopropyl-4-[[[(2,4-dichlorobenzoyl)amino]methyl]-1-(propylsulfonyl)- (CA INDEX NAME)




RN 919284-75-6 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-76-7 CAPLUS
 CN 4-Piperidinecarboxamide, 4-[[[(2,4-dichlorobenzoyl)amino]methyl]-N-[(3-methyl-3-oxetanyl)methyl]-1-(propylsulfonyl)- (CA INDEX NAME)




RN 919284-77-8 CAPLUS
 CN Benzamide, N-[[4-[(3-amino-1-azetidiny]carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]-2,4-dichloro- (CA INDEX NAME)




RN 919284-80-3 CAPLUS

CN Benzamide, N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-81-4 CAPLUS


CN Benzamide, N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 919284-82-5 CAPLUS
 CN Benzamide, 2-chloro-4-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-83-6 CAPLUS
 CN Benzamide, 2-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 919284-84-7 CAPLUS
 CN Benzamide, 4-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 919284-85-8 CAPLUS

CN Benzamide, 3-chloro-2,6-difluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-86-9 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-87-0 CAPLUS

CN Benzamide, 2,4-dichloro-5-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-88-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




IT 919284-68-7P 919284-69-8P 919284-70-1P
 919284-90-5P 919284-91-6P 919284-92-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, GlyT1 inhibitory activity and SAR of
 [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides
 starting from N-Boc cyanopiperidine using amidation as key steps)
 RN 919284-68-7 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-[(phenylmethoxy)methyl]-1-(propylsulfonyl)-4-
 piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-69-8 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-(hydroxymethyl)-1-(propylsulfonyl)-4-
 piperidinyl]methyl]- (CA INDEX NAME)




RN 919284-70-1 CAPLUS
 CN 4-Piperidinecarboxylic acid, 4-[[[(2,4-dichlorobenzoyl)amino]methyl]-1-
 (propylsulfonyl)- (CA INDEX NAME)




RN 919284-90-5 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-[(phenylmethoxy)methyl]-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 919284-91-6 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-(hydroxymethyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 919284-92-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[1-[(2,4-dichlorobenzoyl)amino]ethyl]-1-(propylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT:

27

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1093266 CAPLUS

DOCUMENT NUMBER: 145:432223

TITLE: Method of treating schizophrenia prodrome
 INVENTOR(S): Woods, Scott W.
 PATENT ASSIGNEE(S): Yale University, USA
 SOURCE: PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2006110724 | A2 | 20061019 | WO 2006-US13444 | 20060411 |
| WO 2006110724 | A3 | 20070322 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006235400 | A1 | 20061019 | AU 2006-235400 | 20060411 |
| CA 2602626 | A1 | 20061019 | CA 2006-2602626 | 20060411 |
| EP 1871165 | A2 | 20080102 | EP 2006-740849 | 20060411 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008535864 | T | 20080904 | JP 2008-505637 | 20060411 |
| PRIORITY APPLN. INFO.: | | | US 2005-670600P | P 20050411 |
| | | | WO 2006-US13444 | W 20060411 |

OTHER SOURCE(S): MARPAT 145:432223

AB The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixts. thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.


IT 852029-09-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating schizophrenia prodrome with NMDA glycine agonist and glycine transporter-1 inhibitor)

RN 852029-09-5 CAPLUS


CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-(CA INDEX NAME)



ACCESSION NUMBER: 2006:342953 CAPLUS
 DOCUMENT NUMBER: 144:369920
 TITLE: Cyclopropyl piperidine glycine transporter inhibitors
 for treatment of neurological and psychiatric
 disorders
 INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Wolkenberg,
 Scott E.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2006039221 | A2 | 20060413 | WO 2005-US34301 | 20050926 |
| WO 2006039221 | A3 | 20060908 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2005292323 A1 20060413 AU 2005-292323 20050926 CA 2581582 A1 20060413 CA 2005-2581582 20050926 EP 1797035 A2 20070620 EP 2005-801197 20050926 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR CN 101031547 A 20070905 CN 2005-80033117 20050926 JP 2008514705 T 20080508 JP 2007-534679 20050926 BR 2005015954 A 20080812 BR 2005-15954 20050926 IN 2007DN01977 A 20070817 IN 2007-DN1977 20070314 US 20080108663 A1 20080508 US 2007-664190 20070328 MX 200703816 A 20070424 MX 2007-3816 20070329 KR 2007058565 A 20070608 KR 2007-707362 20070330 NO 2007002208 A 20070427 NO 2007-2208 20070427 PRIORITY APPLN. INFO.: US 2004-614942P P 20040930 WO 2005-US34301 W 20050926 | | | | |

OTHER SOURCE(S): MARPAT 144:369920
 GI




AB The present invention is directed to cyclopropyl piperidine compds. (I; R1 = substituted Ph, substituted heterocycle, (un)substituted C1-8 alkyl, (un)substituted C3-6 cycloalkyl; R2 = (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl; R3,R4 = H, (un)substituted C1-6 alkyl; A = O, NR5; R5 = H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl, benzyl, phenyl; m = 0, 1) that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

IT 882034-97-1P 882034-98-2P 882035-07-6P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclopropyl piperidine compds. as glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)


RN 882034-97-1 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 882034-98-2 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-6-fluoro- (CA INDEX NAME)




RN 882035-07-6 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1220538 CAPLUS
 DOCUMENT NUMBER: 143:472603
 TITLE: Morpholinyl piperidine derivative glycine transporter GlyT1 inhibitors, their preparation/., and their use for treatment of neurological and psychiatric disorders
 INVENTOR(S): Lindsley, Craig W.; Wolkenberg, Scott E.; Zhao, Zhijian
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2005107469 | A2 | 20051117 | WO 2005-US15134 | 20050429 |
| WO 2005107469 | A3 | 20060629 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20070249606 | A1 | 20071025 | US 2006-579234 | 20061030 |
| PRIORITY APPLN. INFO.: | | | US 2004-568201P | P 20040505 |
| | | | WO 2005-US15134 | W 20050429 |

OTHER SOURCE(S): MARPAT 143:472603
GI



AB The invention discloses morpholinyl piperidine compds. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. Preparation of I is described.


IT 869463-15-0P 869463-16-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(morpholinyl piperidine derivative glycine transporter GlyT1 inhibitor preparation and use for treatment of neurol. and psychiatric disorders)


RN 869463-15-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 869463-16-1 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1103490 CAPLUS

DOCUMENT NUMBER: 143:386922

TITLE: Preparation of heteroaryl-substituted piperidine glycine transporter inhibitors for the treatment of psychiatric disorders

INVENTOR(S): Blackaby, Wesley; Duggan, Mark E.; Hallett, David; Hartman, George D.; Jennings, Andrew S.; Leister, William H.; Lewis, Richard T.; Lindsley, Craig W.; Naylor, Elizabeth; Street, Leslie J.; Wang, Yi; Wisnoski, David D.; Wolkenberg, Scott E.; Zhao, Zhijian

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|------------------|----------|
| WO 2005094514 | A2 | 20051013 | WO 2005-US9810 | 20050323 |
| WO 2005094514 | A3 | 20060420 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2005228133 | A1 | 20051013 | AU 2005-228133 | 20050323 |
| CA 2560256 | A1 | 20051013 | CA 2005-2560256 | 20050323 |
| EP 1729772 | A2 | 20061213 | EP 2005-726105 | 20050323 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV | | | |
| CN 1933836 | A | 20070321 | CN 2005-80009593 | 20050323 |
| JP 2007530576 | T | 20071101 | JP 2007-505167 | 20050323 |

| | | | | |
|------------------------|----|----------|-----------------|------------|
| IN 2006CN03155 | A | 20070608 | IN 2006-CN3155 | 20060831 |
| US 20070254880 | A1 | 20071101 | US 2007-593950 | 20070510 |
| PRIORITY APPLN. INFO.: | | | US 2004-555925P | P 20040324 |
| | | | WO 2005-US9810 | W 20050323 |

OTHER SOURCE(S): CASREACT 143:386922; MARPAT 143:386922
GI



- AB Title compds. I [R1 = H, alkyl, halo, Ph, etc.; R2 = (un)substituted Ph, heterocyclyl, alkyl, etc.; R3 = alkyl, cycloalkyl, etc.; R4-5 = H, alkyl, etc.; R6 = H, alkyl; W, X, Y, Z = C, N with the proviso that at least two of W, X, Y and Z are C, to form a pyridine, oxodihydropyridine, etc.; A = O, (un)substituted N; m = 0-1] are prepared For instance, II is prepared in 5 steps from 2-fluoropyridine, tert-Bu 4-cyanopiperidine-1-carboxylate, n-PrSO2Cl and 2-chloro-3,6-difluorobenzoyl chloride. I inhibit the glycine transporter GlyT1 [no data] and are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
- IT 866559-77-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryl-substituted piperidine glycine transporter inhibitors for treatment of psychiatric disorders)
- RN 866559-77-5 CAPLUS
- CN Benzamide, 2,4-dichloro-N-[[4-(6-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl)methyl]- (CA INDEX NAME)




IT 866558-67-0P 866558-68-1P 866558-69-2P
 866558-71-6P 866558-72-7P 866558-73-8P
 866558-74-9P 866558-75-0P 866558-76-1P
 866558-77-2P 866558-78-3P 866558-79-4P
 866558-80-7P 866558-81-8P 866558-82-9P
 866558-83-0P 866558-84-1P 866558-85-2P
 866558-86-3P 866558-87-4P 866558-93-2P
 866558-94-3P 866558-95-4P 866558-96-5P
 866558-99-8P 866559-00-4P 866559-01-5P
 866559-02-6P 866559-10-6P 866559-11-7P
 866559-12-8P 866559-13-9P 866559-14-0P
 866559-15-1P 866559-16-2P 866559-17-3P
 866559-29-7P 866559-30-0P 866559-31-1P
 866559-32-2P 866559-45-7P 866559-46-8P
 866559-48-0P 866559-49-1P 866559-50-4P
 866559-54-8P 866559-55-9P 866559-56-0P
 866559-57-1P 866559-59-3P 866559-62-8P
 866559-64-0P 866559-71-9P 866559-75-3P
 866559-76-4P 866559-78-6P 866559-79-7P
 866559-80-0P 866559-81-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of heteroaryl-substituted piperidine glycine transporter
 inhibitors for treatment of psychiatric disorders)


RN 866558-67-0 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-68-1 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 866558-69-2 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-71-6 CAPLUS
 CN Benzamide, 2-chloro-3,6-difluoro-N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866558-72-7 CAPLUS
 CN Benzamide, 2-chloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-73-8 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-74-9 CAPLUS

CN Benzamide, 2-bromo-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-75-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-76-1 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-77-2 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-78-3 CAPLUS

CN Benzamide, 2-fluoro-6-methoxy-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-79-4 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-80-7 CAPLUS

CN Benzamide, 2-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 866558-81-8 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-82-9 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-83-0 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-84-1 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-85-2 CAPLUS

CN Benzamide, 2-chloro-4-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-86-3 CAPLUS

CN Benzamide, 4-chloro-2-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-87-4 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(4-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-93-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(3-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-94-3 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[1-(propylsulfonyl)-4-(3-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-95-4 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-96-5 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[1-(propylsulfonyl)-4-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866558-99-8 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[4-[6-(4-morpholinyl)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-00-4 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-[6-(4-morpholinyl)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-01-5 CAPLUS

CN Benzamide, 2,4,5-trifluoro-N-[[4-(6-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-02-6 CAPLUS

CN Benzamide, 2,4-dichloro-5-fluoro-N-[[4-(6-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-10-6 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-11-7 CAPLUS

CN Benzamide, N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 866559-12-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-methyl-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-13-9 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[1-methyl-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-14-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 866559-15-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 866559-16-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 866559-17-3 CAPLUS
 CN Benzamide, 2-chloro-3,6-difluoro-N-[(1S)-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 866559-29-7 CAPLUS
 CN Benzamide, 2-chloro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-30-0 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-31-1 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-32-2 CAPLUS

CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-45-7 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(3-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-46-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-[6-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-48-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-[4-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-49-1 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(3-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-50-4 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(3-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-54-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyrazinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-55-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[1-[(3-fluoropropyl)sulfonyl]-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-56-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-[(3-fluoropropyl)sulfonyl]-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-57-1 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1-[(3-fluoropropyl)sulfonyl]-4-(3-fluoro-2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-59-3 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(3-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-62-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-(3-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-64-0 CAPLUS

CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-(propylsulfonyl)-4-[6-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-71-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-(3-fluoropropyl)sulfonyl]-4-[3-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-75-3 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-(3-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 866559-76-4 CAPLUS

CN Benzamide, N-[[4-(3-bromo-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2,4-dichloro- (CA INDEX NAME)




RN 866559-78-6 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-(6-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 866559-79-7 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(1,6-dihydro-6-oxo-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-80-0 CAPLUS


CN Benzamide, 2,4-dichloro-N-[[4-(3-hydroxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-81-1 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(2-methyl-1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:451128 CAPLUS
 DOCUMENT NUMBER: 142:476263
 TITLE: 4-Phenylpiperidine derivative glycine transporter inhibitors for the treatment of neurological and psychiatric disorders
 INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|------------------|------------|
| WO 2005046601 | A2 | 20050526 | WO 2004-US37359 | 20041110 |
| WO 2005046601 | A3 | 20050818 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2004289290 | A1 | 20050526 | AU 2004-289290 | 20041110 |
| CA 2544981 | A1 | 20050526 | CA 2004-2544981 | 20041110 |
| EP 1684759 | A2 | 20060802 | EP 2004-810610 | 20041110 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | |
| CN 1878551 | A | 20061213 | CN 2004-80033295 | 20041110 |
| JP 2007512251 | T | 20070517 | JP 2006-539749 | 20041110 |
| IN 2006DN01895 | A | 20070615 | IN 2006-DN1895 | 20060407 |
| US 20070105902 | A1 | 20070510 | US 2006-579261 | 20060511 |
| PRIORITY APPLN. INFO.: | | | US 2003-519348P | P 20031112 |
| | | | WO 2004-US37359 | W 20041110 |

OTHER SOURCE(S): MARPAT 142:476263

AB The invention discloses 4-phenylpiperidine derivs. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine

transporter GlyT1 is involved. Compound preparation is described.


IT 852029-09-5P 852029-11-9P 852029-12-0P
852029-13-1P 852029-16-4P 852029-17-5P
852029-18-6P 852029-21-1P 852029-22-2P
852029-23-3P 852029-24-4P 852029-25-5P
852029-26-6P 852029-27-7P 852029-28-8P
852029-31-3P 852029-32-4P 852029-33-5P
852029-34-6P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-41-5P 852029-42-6P
852029-43-7P 852029-44-8P 852029-46-0P
852029-47-1P 852029-48-2P 852029-49-3P
852029-50-6P 852029-51-7P 852029-52-8P
852029-53-9P 852029-54-0P 852029-55-1P
852029-56-2P 852029-57-3P 852029-58-4P
852029-59-5P 852029-60-8P 852029-61-9P
852029-62-0P 852029-63-1P 852029-64-2P
852029-65-3P 852029-66-4P 852029-67-5P
852029-68-6P 852029-69-7P 852029-70-0P
852029-71-1P 852029-72-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(phenylpiperidine derivative glycine transporter inhibitors for treatment
of neurol. and psychiatric disorders)


RN 852029-09-5 CAPLUS

CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
(CA INDEX NAME)




RN 852029-11-9 CAPLUS

CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
(CA INDEX NAME)




RN 852029-12-0 CAPLUS

CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
(CA INDEX NAME)




RN 852029-13-1 CAPLUS

CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
(CA INDEX NAME)




RN 852029-16-4 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
(CA INDEX NAME)




RN 852029-17-5 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)-
(CA INDEX NAME)




RN 852029-18-6 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)-
(CA INDEX NAME)




RN 852029-21-1 CAPLUS

CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-22-2 CAPLUS

CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 852029-23-3 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 852029-24-4 CAPLUS

CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-25-5 CAPLUS

CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-26-6 CAPLUS

CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-27-7 CAPLUS

CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-28-8 CAPLUS

CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-31-3 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-32-4 CAPLUS

CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-33-5 CAPLUS

CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-34-6 CAPLUS


CN Benzamide, 2-(2,2-difluoroacetyl)-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 852029-35-7 CAPLUS
 CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
 (CA INDEX NAME)




RN 852029-36-8 CAPLUS
 CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-
 piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
 CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-
 piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-38-0 CAPLUS
 CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-
 (trifluoromethyl)- (CA INDEX NAME)




RN 852029-39-1 CAPLUS

CN Benzamide, 2-amino-6-(trifluoromethyl)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS


CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-41-5 CAPLUS

CN Benzamide, 2-(2,2-difluoroacetyl)-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-42-6 CAPLUS

CN Benzamide, 2-[(difluoromethyl)thio]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-43-7 CAPLUS

CN Benzamide, 2,3-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-44-8 CAPLUS

CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-46-0 CAPLUS

CN Benzamide, 2,5-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-47-1 CAPLUS

CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 852029-48-2 CAPLUS


CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-49-3 CAPLUS


CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-50-6 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-51-7 CAPLUS

CN Benzamide, 2-chloro-6-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-52-8 CAPLUS


CN Benzamide, 2-bromo-3-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852029-53-9 CAPLUS

CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 852029-54-0 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-55-1 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-56-2 CAPLUS


CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)




RN 852029-57-3 CAPLUS
 CN Benzamide, N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 852029-58-4 CAPLUS
 CN Benzamide, 2-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-59-5 CAPLUS
 CN Benzamide, 4-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)




RN 852029-60-8 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)




RN 852029-61-9 CAPLUS

CN Benzamide, 2,4-dichloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)




RN 852029-62-0 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)




RN 852029-63-1 CAPLUS

CN Benzamide, N-[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-64-2 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-65-3 CAPLUS

CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-66-4 CAPLUS

CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-67-5 CAPLUS


CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
 CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-
 [[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)




RN 852029-69-7 CAPLUS
 CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 852029-70-0 CAPLUS
 CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-
 [[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-71-1 CAPLUS
 CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852029-72-2 CAPLUS

CN Benzamide, 2-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:855758 CAPLUS

DOCUMENT NUMBER: 139:364829

TITLE: Preparation of heterocyclo inhibitors of potassium channel function

INVENTOR(S): Lloyd, John; Jeon, Yoon T.; Finlay, Heather; Yan, Lin; Beaudoin, Serge; Gross, Michael F.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Icagen, Inc.

SOURCE: PCT Int. Appl., 330 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2003088908 | A2 | 20031030 | WO 2003-US11807 | 20030416 |
| WO 2003088908 | A3 | 20040527 | | |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003223651 A1 20031103 AU 2003-223651 20030416
 EP 1501467 A2 20050202 EP 2003-719792 20030416
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005529114 T 20050929 JP 2003-585661 20030416
 NO 2004004351 A 20041013 NO 2004-4351 20041013
 PRIORITY APPLN. INFO.: US 2002-374279P P 20020419
 WO 2003-US11807 W 20030416
 OTHER SOURCE(S): MARPAT 139:364829
 GI



- AB The title compds. [I; m, p = 0-3 (provided that the sum of m and p is at least 2); Q = NR¹, O, S, SO, SO₂; R¹ = H, C(:W)NR⁶R⁷, SO₂NR⁶R⁷, OCONR⁶R⁷, etc.; R² = heteroaryl, heteroarylalkyl, aryl, etc.; J = a bond, alkylene; R³ = R⁵, OR⁵, SO₂R⁵, etc.; R⁵ = CN, heteroaryl, aryl, etc.; R⁶, R⁷ = H, alkyl, OH, etc.; W = (un)substituted NH, N(CO₂H), N(CN), N(SO₂H), CH(NO₂); Rx = H, alkyl, hydroxyalkyl, aryl, etc.], useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K⁺ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K⁺ current I_{Kur}) in the prevention and treatment of arrhythmia and I_{Kur}-associated conditions, were prepared E.g., a multi-step synthesis of II [starting from bis(2-chloroethyl)amine], was given. Pharmaceutical composition comprising the compound I is claimed.
- IT 619277-83-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted piperidines as inhibitors of potassium channel function)
- RN 619277-83-7 CAPLUS
 CN Benzamide, 2-methoxy-N-[[1-(propylsulfonyl)-4-(2-thienyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:314546 CAPLUS

DOCUMENT NUMBER: 132:321801

TITLE: Preparation of 4-[(benzoylamino)methyl]piperidines and analogs as potassium channel inhibitors

INVENTOR(S): Bao, Jianming; Kayser, Frank; Kotliar, Andrew; Parsons, William H.; Rupprecht, Kathleen M.; Claiborne, Christopher F.; Liverton, Nigel; Claremon, David A.; Thompson, Wayne J.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2000025786 | A1 | 20000511 | WO 1999-US25066 | 19991026 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6303637 | B1 | 20011016 | US 1999-422500 | 19991021 |
| CA 2348735 | A1 | 20000511 | CA 1999-2348735 | 19991026 |
| CA 2348735 | C | 20071211 | | |
| EP 1126849 | A1 | 20010829 | EP 1999-955169 | 19991026 |
| EP 1126849 | B1 | 20050309 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002528503 | T | 20020903 | JP 2000-579227 | 19991026 |
| AU 764515 | B2 | 20030821 | AU 2000-11338 | 19991026 |
| AT 290382 | T | 20050315 | AT 1999-955169 | 19991026 |
| PRIORITY APPLN. INFO.: | | | US 1998-106292P | P 19981030 |
| | | | WO 1999-US25066 | W 19991026 |

OTHER SOURCE(S): MARPAT 132:321801

GI




AB Title compds. [I; R1 = CH₂NR₁₀COR₆; R₂,R₆ = (un)substituted Ph; R₃,R₄ = H, halo, alkyl, acyl, etc.; R₁₀ = H, alkyl, acyl, etc.; Z = O, SO₀-2, NR₅; R₅ = H, OH, alkyl, acyl, etc.; Z₁,Z₂ = bond, CH₂, CH₂CH₂] were prepared as potassium channel inhibitors (no data). Thus, 4-cyano-1-benzyl-4-phenylpiperidine was reduced and the product N-acylated by 2-(MeO)C₆H₄COCl to give, after deprotection and Ac₂O acylation, 2-(MeO)C₆H₄CONHCH₂Z₃Ac (Z₃ = 4-phenylpiperidine-4,1-diyl).

IT 266341-42-8P 266341-43-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-[(benzoylamino)methyl]piperidines and analogs as potassium channel inhibitors)


RN 266341-42-8 CAPLUS

CN Benzamide, 2-methoxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-
 (CA INDEX NAME)



RN 266341-43-9 CAPLUS

CN Benzamide, N-[[1-(butylsulfonyl)-4-phenyl-4-piperidinyl]methyl]-2-methoxy-
 (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

| | | |
|--|---------------------|-------------------|
| FULL ESTIMATED COST | ENTRY 64.75 | SESSION 243.32 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -8.80 | -8.80 |

STN INTERNATIONAL LOGOFF AT 16:20:07 ON 15 OCT 2008